Friday, 20 April 2018 - 19:25
  • it
  • de
  • en
  • fr

Tecentriq

Good Phase III results for Roche’s Tecentriq

Switzerland-based group Roche yesterday issued a press release announcing that its immunotherapy tecentriq (atezolizumab) has delivered positive results in combination with chemotherapy (carboplatin and Abraxane). The data have been collected during the Phase III IMpower131 clinical trial, conducted on patients…

Pharma sector dynamics and Roche’s strategy

The pharmaceutical market maintains its consolidation trend, as confirmed by recent figures from Evaluate Pharma. The global drug market was worth $770bn in 2016 and as much as 20% of this value was generated by the top 4 of the…

Roche’s Tecentriq fails Phase III trial for bladder cancer treatment

Roche issued a press release announcing that blockbuster PD-L1 tecentriq (atezolizumab) did not meet its primary endpoint for the treatment of bladder cancer. The Phase III IMvigor211 clinical study, which assessed tecentriq, showed that the new therapy, tested on a…

Roche 2016 Q3: oncology medicines still the core business of the group

Swiss pharma group Roche reported yesterday its first nine months 2016 and third quarter 2016 results. In the first 9 months of the year, Roche’s sales increased by 4%, to CHF37.9bn, exceeding analysts’ forecasts, that is CHF37.7bn. Such growth originates…

Tecentriq (Roche) approved in US for lung cancer treatment

The new Roche’s immunotherapy, Tecentriq (atezolizumab), was approved by FDA for metastatic lung cancer treatment (second-line treatment), regardless of patients’ PD-L1 status, which indicates the potential immunotherapy response. The data used by FDA for the approval showed that patients treated…